NCT03932409View on ClinicalTrials.gov

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

February 28, 2026

Conditions
Endometrial Cancer
Interventions
DRUG

Pembrolizumab

"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"

RADIATION

Vaginal cuff brachytherapy (VCB)

Treatment should commence within 12 weeks of the surgery/hysterectomy

DRUG

Paclitaxel

after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles

DRUG

Carboplatin

after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles

Trial Locations (2)

70112

LSU Health New Orleans, New Orleans

73104

Stephenson Cancer Center, Oklahoma City

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Oklahoma

OTHER

NCT03932409 - Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer | Biotech Hunter | Biotech Hunter